Zentalis Pharmaceuticals ( (ZNTL) ) just unveiled an announcement.
Zentalis Pharmaceuticals has announced a significant update that the FDA has lifted the partial clinical hold on azenosertib studies, allowing the company to proceed with its clinical trials. This news is particularly relevant for investors and those tracking advancements in cancer treatments, as azenosertib is a promising drug targeting the WEE1 protein to prevent cancer cell replication. Zentalis is set to present important clinical data later in the year and remains confident in meeting its data guidance for 2024, marking an important milestone for the company’s development program.
See more data about ZNTL stock on TipRanks’ Stock Analysis page.
